

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2741342

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CEPTARIS THERAPEUTICS, INC.	11/04/2013
RECEIVING PARTY DATA	
Name:	ACTELION PHARMACEUTICALS, LTD.
Street Address:	GEWERBESTRASSE 16
City:	ALLSCHWIL
State/Country:	SWITZERLAND
Postal Code:	CH-4123
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14153914
CORRESPONDENCE DATA	
Fax Number:	
Phone:	(202) 973-8800
Email:	cedwards@wsgr.com
<i>Correspondence will be sent via US Mail when the email attempt is unsuccessful.</i>	
Correspondent Name:	WSGR DC IP GROUP
Address Line 1:	1700 K STREET, NW
Address Line 2:	FIFTH FLOOR
Address Line 4:	WASHINGTON, DISTRICT OF COLUMBIA 20006
ATTORNEY DOCKET NUMBER:	45709-701.305
NAME OF SUBMITTER:	CHRIS MCANDREW
Signature:	/Chris McAndrew/
Date:	02/25/2014
Total Attachments: 2 source=CeptarisTherapeuticsInc_to_ActelionPharmaceuticalsLtd_Assignment#page1.tif source=CeptarisTherapeuticsInc_to_ActelionPharmaceuticalsLtd_Assignment#page2.tif	

CORPORATE TO CORPORATE ASSIGNMENT

Docket Number 37892-700

WHEREAS, Ceparis Therapeutics, Inc., a corporation of the State of Pennsylvania (hereinafter "Assignor"), owns the entire right, title and interest in and to the inventions disclosed in the patents and applications as set forth in Annex A hereto (such patents and patent applications hereinafter collectively referred to as "Applications");

WHEREAS, Actelion Pharmaceuticals Ltd., a corporation headquartered in the Country of Switzerland (hereinafter "Assignee"), is desirous of acquiring the entire right, title and interest in and to said Applications, and the inventions disclosed therein, and in and to all embodiments of the inventions, (hereinafter collectively referred to as "Inventions"), and in and to any and all patents, inventor's certificates and other forms of protection thereon granted in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise (hereinafter "Patents").

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to said Inventions; (b) in and to said Applications and any application or Patent claiming priority to or common priority with the Applications, including the right to claim priority to and from said Application(s); (c) in and to each and every application that is a divisional, substitution, continuation, or continuation-in-part of any of said Applications; (d) in and to said Patents and each and every Patent issuing or reissuing from any of the foregoing; (e) in and to each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing; and (f) in and to each and every Patent and application filed outside the United States and corresponding to any of the foregoing.

2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.

4. Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

5. Said Assignor hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

6. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee as of the date written below.

ASSIGNOR:

Date:

March 4, 2010

By:

Name:

Doug Snyder

Title:

General Counsel US

RECEIVED AND AGREED TO BY ASSIGNEE:

Date:

30 October 2013

By:

Name:

Oliver Peinelt

Title:

Frank Schager

Senior Director Chief Patent Counsel

Assignment by Ceptaris Therapeutics, Inc., to Actelion Pharmaceuticals Ltd.
Annex A

Application No. / Patent No.
61/039,840
PCT/US2009/036737
13/930,535
13/911,282
13/911,217
13/300,021
13/735,710
12/890,183
8,501,819
8,501,818
8,501,817
7,838,564
7,872,050
8,450,375
60/661,356
60/751,128
PCT/US2006/009060
61/537,153
61/506,222
13/546,149
PCT/US12/046155